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Abstract
Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. 
Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing 
diseases each with different treatments and prognoses. Therefore, timely and accurate 
recognition of the underlying cause for PHT is essential for appropriate management. This is 
especially true for patients with Pulmonary Arterial Hypertension (PAH) in the current era of 
disease-specific drug therapy.
Measurement of Pulmonary Vascular Resistance (PVR) helps separate pre-capillary from 
post-capillary PHT, and is measured with right heart catheterisation (RHC). 
Echocardiography has been used to derive a number of non-invasive surrogates for PVR, 
with varying accuracy. Ultimately, the goal of non-invasive assessment of PVR is to separate 
PHT due to left heart disease from PHT due to increased PVR, to help streamline 
investigation and subsequent treatment.
In this review, we summarise the physiology and pathophysiology of pulmonary blood flow, 
the various causes of pulmonary hypertension, and non-invasive surrogates for PVR.
Keywords: Pulmonary hypertension (PHT); Doppler echocardiography; Pulmonary arterial 
hypertension; Pulmonary vascular resistance (PVR); Heart failure with preserved ejection 
fraction (HFpEF)
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Introduction
Pulmonary Hypertension (PHT), defined by a mean pulmonary artery pressure at or above 25
mmHg, can be broadly differentiated physiologically into pulmonary arterial hypertension
(PAH) due to increased pulmonary vascular resistance (PVR), PHT due to increased 
pulmonary venous pressure but with a normal PVR (usually due to left heart disease), or a 
combination of both abnormalities. This differentiation is a crucial step in the investigation of 
patients with PHT, since the treatment of PHT due to left heart disease is fundamentally 
different from PHT due to abnormally increased pulmonary vascular resistance. Simply 
identifying the presence of PHT is necessary but not sufficient to manage such patients, and
measurement of PVR is a key step. However, assessment of PVR usually requires right heart 
catheterisation (RHC), which is invasive, has potential complications, and therefore not 
universally performed in the investigation of PHT. 
Pulmonary hypertension is relatively common and associated with a high risk of death(1), yet 
often goes unrecognised for extended periods. Regardless of aetiology, the common 
consequence of all forms of untreated PHT is symptomatic breathlessness, progressive right 
ventricular failure and ultimately death. With the development of effective advanced therapy 
for PAH, there is a need for simple non-invasive tools that can estimate PVR and help 
identify patients who would benefit from more comprehensive investigation, including right 
heart catheterisation. In this review, we will review and summarise the biochemical 
compounds and mechanical variables that affect blood flow through the pulmonary 
vasculature. We will also summarise techniques that have been used to non-invasively 
estimate PVR.
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Physiology of Pulmonary Blood Flow and Pulmonary Vascular Resistance 
Normal pulmonary circulation is low-pressure, low-resistance and highly dynamic, which 
allows major increases in pulmonary blood flow in response to exercise with only small 
increases in pressure. Pulmonary arterial blood flow regulation is maintained by pulmonary 
vascular resistance and recruitment of additional pulmonary capillaries, without the option of 
diversion through different vascular beds. This differs markedly from the systemic 
circulation, in which exercise results in hyperaemia in skeletal muscles, flow-mediated 
dilatation of conduit arteries, and dynamic changes in peripheral vascular resistance for each
relevant vascular bed.  
The degree of pulmonary arterial tone, via smooth muscle contraction, is governed by a series 
of vasoactive compounds released by the pulmonary vascular endothelium. Patients with 
PAH have increased levels of compounds that are responsible for vasoconstriction, 
thrombosis and smooth muscle cell hyperplasia (2-4). Each of the compounds exerts different 
effects on vascular smooth muscle, endothelial cell, surrounding blood cell responses. These 
responses are summarised in Table 1.
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Table 1: Vasoactive compounds affecting pulmonary vascular resistance and drugs for PHT 
targeting those compounds
Compounds Effects Therapeutic agents modulating 
these compounds
Thromboxane A2
(TxA2)
Vasoconstrictor, stimulator of 
platelet aggregation and 
proliferation
None
Prostacyclin Vasodilator, inhibitor of platelet 
aggregation and has 
antiproliferative property 
(counteracts thromboxane A2)
Epoprostenol, Iloprost
Endothelin-1 
(ET-1)
Potent vasoconstrictor and 
stimulator of pulmonary artery 
smooth muscle cells  proliferation
Endothelin receptor antagonists
(e.g. bosentan, macitentan)
Nitric Oxide 
(NO)
Vasodilator and inhibitor of platelet 
activation and vascular smooth-
muscle cell proliferation, 
counteracts endothelin-1’s actions
Inhaled NO
Phosphodiesterase inhibitors (e.g. 
sildenafil) reduced the inactivation 
of cyclic guanosine 
monophosphate through which NO 
mediates its effects
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Serotonin Vasoconstrictor No therapeutic agent available 
currently
Pulmonary blood flow is further regulated via capillary recruitment. In states of resting 
cardiac output, a number of capillary beds are in a collapsed state having neither blood 
perfusion nor ventilation. As the CO increases, there is an increase in the capillary blood 
volume resulting in recruitment of these distensible capillary beds without an increase in 
PVR. 
Despite the responsive nature of this system, many additional factors affect pressure through 
the pulmonary vasculature. The Hagen-Poiseuille equation below describes the relationship 
between pressure, flow, viscosity and radius in a hollow, straight, non-distensible tube (5). 
= pressure change
= length of pipe
= dynamic viscosity
= volumetric flow rate
= radius
The change in pressure across the pulmonary artery is inversely proportional to the fourth 
power of the radius. If the radius of the pulmonary artery decreases (e.g. due to smooth 
muscle hypertrophy, hypoxic vasoconstriction or pulmonary thromboembolic disease), there 
is an accompanying disproportionate increase in the pressure across the pulmonary artery, 
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and a higher up-stream pressure will be required in order to maintain normal down-stream 
pressures.
There are additional effects on pulmonary pressures from blood viscosity (e.g. hyperviscosity 
syndromes increase pulmonary pressures whereas anaemia decreases pulmonary pressures or 
increased blood flow rates (high cardiac output or valvular disease).
Finally, the dynamics of blood flow in the left heart affect pulmonary blood flow. In a normal 
heart, left ventricular relaxation during diastole is an active (ATP dependent) process, causing 
a rapid fall in ventricular pressure and a “suction” effect on left atrial blood. This results in 
relative emptying of the pulmonary vein blood into the left atrium, and a fall in pulmonary 
capillary pressure. Further, during ventricular systole, the downward motion of the mitral 
valve toward the ventricular apex elongates the left atrium creating a systolic “suction” effect 
on pulmonary vein blood. Simultaneous right ventricular systolic contraction ensures a 
constant supply of blood into this low pressure circuit with rapid pulmonary capillary transit. 
These events cause efficient systolic and diastolic pulmonary capillary blood transit.
Conditions that decrease left ventricular and left atrial compliance such as chronic atrial 
fibrillation, the stiff left atrial syndrome(6, 7), left ventricular hypertrophy and restrictive 
cardiomyopathy(8), disrupt the finely balanced transit through the pulmonary circulation and 
increase pulmonary capillary pressures.
Measurement of Pulmonary Vascular Resistance 
In humans in vivo, pulmonary haemodynamics are most accurately measured invasively using 
right heart catheterisation. The mean pulmonary artery pressure (mPAP) can be measured by 
averaging the pressure inside the pulmonary artery throughout the cardiac cycle. To measure 
the pulmonary capillary wedge pressure (PCWP), the catheter is advanced into a branch 
pulmonary artery, and a small balloon attached near the tip of the catheter is inflated until the 
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pulmonary artery is occluded. The mean pressure measured at the tip of the catheter is taken 
to be the back-pressure from the left heart, and approximates the left atrial pressure in the 
absence of pulmonary vein stenosis. A mean PCWP <15 mmHg is generally accepted to 
indicate normal left atrial mean pressure, and is required to diagnose PAH, excluding PHT 
due to left heart disease(9).
The PVR is the resistance generated by the pulmonary vasculature against which the blood 
must travel from right to left side of the heart and is influenced by the transpulmonary 
gradient and the cardiac output:
PVR = TPG/CO
TPG = mPAP-PCWP
TPG – Transpulmonary gradient
mPAP – mean Pulmonary Artery Pressure in mmHg
PCWP – Pulmonary Capillary Wedge Pressure in mmHg
CO – Cardiac Output in L/min
In general, the higher the TPG and/or the lower the CO, the higher the PVR. Pulmonary 
vascular resistance is preferred to TPG, since it takes blood flow into account (10). The 
equivalent measure in the systemic circulation, the systemic vascular resistance (SVR), is 
generated by a number of different systemic arterial vascular beds and is approximately 10-
fold higher than the PVR. A normal PVR is 1–3 mmHg.min/L, and decreases further with 
exercise and increased CO. For convenience, the mmHg.min/L units are often dropped and
presented as Wood Units (WU), in honour of Earl Wood, an early pioneer in the field.
Despite its importance in PHT diagnosis and management, RHC has a number of drawbacks. 
It is invasive with potentially serious risks such as ventricular arrhythmias, 
thromboembolism, myocardial or valvular injury, pulmonary infarction and rupture of a
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pulmonary artery. Right heart catheterisation requires significant skills and standardisation of 
the procedure, and is not universally available. Although RHC accurately measures the 
PCWP, it may not reflect the true left ventricular filling pressure (11, 12), particularly if 
mitral stenosis (13), pulmonary vein stenosis or a noncompliant left atrium (6) is present. 
Clinical Classification and Epidemiology of Pulmonary Hypertension
Pulmonary hypertension is defined as an increased resting mPAP at or above 25 mmHg, 
measured with RHC (9). Pulmonary hypertension is not a disease in itself, but simply a 
marker of a pathophysiological abnormality that requires explanation. A clinical 
classification of PHT has been provided by the World Health Organisation (WHO) with 
several more recent updates (14). The Latest Classification (NICE 2013) classified PHT into 
five groups, summarised in Table 2.
Table 2: NICE classification of pulmonary hypertension, with abridged examples for each 
group. 
Pulmonary Hypertension Group Examples
Group 1
Pulmonary Arterial Hypertension
Idiopathic PAH
PAH associated with other diseases:
Scleroderma
Congenital heart disease
Group 2
PHT due to Left Heart Disease
Myocardial disorders:
Valvular heart disease
Congenital LV inflow or outflow obstruction
Group 3
PHT due to Lung Disease
COPD and Interstitial lung disease
Sleep disorders
Chronic hypoxia
Group 4 Multiple chronic pulmonary emboli
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Chronic Pulmonary Thromboembolic 
Disease (CTEPH)
Group 5
PHT with multifactorial cause
Haematologic disorders
Chronic renal failure
The data from recent studies suggest the true prevalence of PHT in the general population is 
higher than previously reported (15-17). We have previously reported a minimum ‘indicative’ 
prevalence for all forms of PHT at 326 cases/100,000 inhabitants of Armadale and its 
surrounding area in Western Australia. Left heart disease-associated PHT was the commonest 
cause (250 cases/100,000) and had the worst prognosis. Patients with PAH who were treated 
with disease specific therapy had the best prognosis (18). Moreover, there is significant delay 
between symptom onset and the time of diagnosis leading to poor prognoses ( 19, 20).
Previously, patients with group 1 PHT (PAH) had worse survival than other groups. The era 
of advanced therapy has improved the overall prognosis of PAH patients (21) with some 
trials suggesting one-year survival rates of 84% (22). Advanced therapy includes specific 
pulmonary vasodilator drugs, such as Prostacyclin, endothelin receptor antagonists (ERAs) 
and phosophodiesterase typ -5 (PDE-5) inhibitors. These decrease the rate of progression and 
complications as well as improve symptoms associated with PAH, with the greatest benefits 
derived from early commencement of therapy.
A Proposed Pathophysiological Classification of PHT based on PVR
The latest clinical classification for pulmonary hypertension only partially reflects the 
underlying pathophysiology of each disease. For this reason, there is an overlap in treatment 
between groups. An alternative method of classification is to describe the pathophysiology 
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underpinning the PHT. Using this method, the causes of PHT can be subdivided into two 
major groups: pre-capillary or post-capillary based on whether the pulmonary vascular 
resistance is normal or increased. Pre-capillary PHT is defined by a high transpulmonary 
gradient of at least 12 mmHg, a high pulmonary vascular resistance of >3 WU and 
pulmonary capillary wedge pressures of <15 mmHg (normal left heart filling pressure). These 
“high PVR” pulmonary hypertension patients may respond to pulmonary vasodilator therapy, 
and would include individuals with Group 1 or Group 3 PHT. Some patients from groups 4 or 
5 may also be included, depending on their PVR.
Post-capillary pulmonary hypertension, or “normal PVR” pulmonary hypertension, is 
characterised by an increased PCWP of >15 mmHg but normal or low PVR(9, 10). These 
patients are predominantly Group 2 (left heart disease). 
Some patients have a mixed picture, with PCWP due to elevated LV filling pressures, but 
with coexisting increased PVR. These individuals have a disproportionate rise in their 
pulmonary artery pressure beyond that expected from the degree of left heart disease alone.
Such patients may respond only partially to diuretic therapy and treatment of their left heart 
disease, however the use of pulmonary vasodilator therapy in this situation is 
controversial(23-26).
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The range of abnormalities are summarised in Figure 1 below.
Figure 1: The range of abnormalities in PHT. Panel A shows a normal scenario with normal 
PVR and normal LV filling pressures. Panel B shows normal LV filling pressures but 
increased PVR resulting in PAH. Panel C demonstrates increased LV filling pressures with 
normal PVR, resulting in pulmonary hypertension due to left heart disease. Panel D shows a 
mixed picture, with increased LV filling pressure but a disproportionate increase in 
pulmonary artery pressure caused by increased PVR. PVR = Pulmonary Vascular Resistance; 
RVSP= right ventricular systolic pressure; LV= left ventricle.
A B
C D
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Identifying increased PVR and/or abnormal left heart filling pressure helps guide therapy, 
particularly in the era of advanced therapies which target the pulmonary vasculature (27-32). 
Heart failure with preserved ejection fraction (HFpEF) causing PHT due to increased filling 
pressures should not be misclassified as PAH (33), particularly since some pulmonary 
vasodilator therapy in this group of patients may be harmful. 
Echocardiography in Pulmonary Hypertension
Echocardiography (echo) is the most commonly used noninvasive tool for identifying PHT, 
and is particularly useful when screening for PHT (34). Using the velocity of tricuspid 
regurgitation (TRV), pulmonary artery systolic pressure (PASP) can be estimated (35-37)
(Figure 2). There is a strong association between the pulmonary artery pressure (PAP) 
measured by right heart catheterisation and that obtained by echo (18, 38). 
PASP = RAP + 4(TRV)2
Figure 2. From Apical 4-chamber view, the tricuspid regurgitation velocity (TRV) is 
measured by using continuous wave Doppler. The PASP is estimated using the modified 
Bernoulli equation (∆P=4V2). P=change in pressure, V=velocity of flow(36).
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Pulmonary Vascular Resistance Estimation with Echocardiography
A number of echocardiographic markers have been proposed for the noninvasive estimation 
of  PVR(39-42). However, many of these markers cannot reliably separate PHT due to left 
heart disease from PHT due to increased PVR. Currently, there is no single reliable method 
of estimating PVR non-invasively that has been tested and proven in a large-scale study.
As early as 1975, researchers have described methods to estimate PVR non-invasively. In a 
study by Hirschfeld et al. (39), 64 patients with congenital heart disease underwent RHCs and 
echo examinations. Fifty-seven patients had both examinations on the same day and four
patients had them within one month; however, three patients’ echoes were done three to five
years after RHC. The ratio of right ventricular ejection time (RVET) to right ventricular pre-
ejection period (RPEP) was found to correlate well with invasive measurements of 
pulmonary artery diastolic pressure (PADP), PVR and mPAP. The correlation coefficient of 
the proposed index with PVR was 0.69. The study was limited to patients with congenital 
heart diseases and extrapolation to PHT patients due to other aetiologies may not be 
appropriate. Dabestani et al. examined the pulmonary artery flow velocities by pulsed 
Doppler echocardiography in 39 patients and found a negative linear correlation between 
pulmonary artery acceleration time and total pulmonary resistance(43). 
Scapellato, and colleagues simultaneously performed Doppler echocardiographic and RHC
measurements in 63 patients with sinus rhythm and severe heart failure(40). Doppler 
measurements from pulmonary flow and TRV curve were correlated with invasive PVR. 
Among the investigated variables, the acceleration time of pulmonary systolic flow was 
found to have best correlation with the invasive PVR (r=-0.68). The correlation coefficient 
improved to 0.96 by using the equation: 
PVR= -0.156+1.154*[(PEP/AcT) /TT]
PEP = Pre-ejection period
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AcT=Pulmonary acceleration time
TT= Total systolic time
The principal advantages of this study were simultaneous measurement of both echo and 
RHC, and the relative simplicity and accuracy of their equation up to 9 WU. However, the 
study was small and excluded patients with atrial fibrillation and those without heart failure.
The formula described by Abbas et al. in 2003 is commonly used in echo laboratories as a 
noninvasive PVR assessment. They performed simultaneous echo and RHC in 44 patients
(41). They found a close association (r=0.93, CI 0.87–0.96) between the invasively measured 
PVR and the ratio of the TRV to the velocity time integral of the flow through the right 
ventricular outflow tract (TVIRVOT,). Their equation approximated to the following: 
PVRECHO =0.16 +10 x TRV/TVIRVOT
This method is easy to calculate from standard echo measurements, but the study was
relatively small, did not include patients with PVR over 6 WU, and did not account for left 
atrial pressure, an essential component of the invasively measured PVR. In subsequent 
analyses, the original Abbas equation was shown to underestimate invasive PVR assessment 
in those with PVR over 6 WU(44), which could be partly corrected by incorporating 
assessment of LV filling pressures into the equation (using E:E’ ratios). The E:E’ ratio is 
calculated as the ratio of the early diastolic flow through the mitral valve (measured using 
pulsed wave Doppler echo) to the early diastolic descent velocity of the medial mitral annulus
(measured using pulsed wave tissue Doppler velocities). The E:E’ ratio is commonly used as 
a surrogate for left ventricular filling pressure (45-47) and predicts mortality in left heart 
disease(48-50). Using data from five separate studies, Abbas et al. demonstrated a more 
robust association between PVR and TRV2/TVIRVOT (42), including patients with a PVR > 6
WU. The ratio has been further validated by a similar study in post-cardiac surgery patients in 
an intensive care setting (51).
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A further study by Haddad et al. in 2009 demonstrated that invasively measured PVR 
correlated well with the index of PASP to the heart rate (HR) times the TVIRVOT [PASP/(HR 
x TVIRVOT)] in 51 patients with established PAH (52). This method is also simple to use and 
the measurements required for the equation are routinely performed in most 
echocardiography laboratories. The small number of participants again limited this study. 
Additional sources of error include the need to estimate the right atrial pressure in their 
equation.
Table 3: Summary of echocardiographic methods for estimating PVR
Investigators and 
References
Surrogate Indexes/Formulae Number 
of 
patients
Correlation 
coefficient (r) of 
surrogate index with 
PVR
Hirschfeld et al. 
(39)
RVET/ RPEP
(RVET= right ventricular ejection 
time,
RPEP =right pre-ejection period.)
64 0.69 
Scapellato et al. 
(40)
PVR=0.156+1.154*[(PEP/AcT) /TT] 
(PEP=Pre-ejection period,
AcT=Acceleration time, 
TT=total systolic time of pulmonary 
flow.)
63 0.96
Abbas et al.
(original) (41)
TRV/TVIRVOT
(VTR= Tricuspid Regurgitation 
Velocity,
44
0.929 (95% 
confidence interval 
0.87 to 0.96) 
Page 17 of 22
Ac
ce
pte
d M
an
us
cri
pt
17
Velocity,
TVIRVOT=Time Velocity Integral of 
the flow through the right ventricular 
outflow tract)
Abbas et al. 
(Analysis of raw 
data from 5 
validation 
studies)(42)
TRV/TVIRVOT (original)
TRV2/TVIRVOT (modified)
150 
patients 
on final 
analysis
0.76
0.79
Haddad et al. (50) PASP/(HR x TVIRVOT) 51 0.860 (95% 
confidence interval, 
0.759-0.920)
Recently, a new echocardiographic method for estimating transpulmonary gradients has been 
proposed by Scalia et al. (53). The ePLAR, or echocardiographic pulmonary to left atrial ratio 
is the ratio of peak tricuspid regurgitation velocity (a marker of pulmonary artery systolic 
pressure) and E:E’ ratio (a marker of left ventricular filling pressure).
ePLAR = Echocardiographic Pulmonary to Left Atrial Ratio
TRV = Tricuspid  Regurgitation Velocity
 = The ratio of transmitral E-wave to septal mitral annular Doppler Tissue Imaging E'-
wave
The marker is simple, non-invasive, and uses measurements performed as part of a standard 
echocardiogram. For 16,356 “normal” echocardiograms without PHT, the mean ePLAR was 
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0.30 +/- 0.09m/s. For 133 patients with PHT, the ePLAR helped separate those with elevated 
PVR from those with PHT due to left heart disease: In 35 patients with pre-capillary PHT
confirmed using RHC (with elevated PVR, mean 6.5+/-3.6 WU), the mean ePLAR was 0.44 
+/- 0.22 m/s. The ePLAR was significantly lower (0.18 +/- 0.18 m/s) in those with PHT due 
entirely to left heart disease (81 patients, mean PVR 3.1+/-2.7 WU). The major limitation of 
the study is non-simultaneous performance of echocardiograms and RHC. Although helpful 
to identify patients with elevated transpulmonary gradients, ePLAR does not take cardiac 
output into account. 
Conclusions
Pulmonary hypertension is common and associated with significant mortality. A rigorous 
approach to its diagnosis is required by every echo laboratory, starting with estimation of 
pulmonary artery pressure. Pulmonary hypertension is not a diagnosis in itself, and 
identification of the underlying cause will determine approaches to treatment. Estimation of 
PVR is an important aspect of the diagnostic workup and a number of non-invasive methods 
for PVR measurement have been proposed. Like their invasive counterparts, most non-
invasive methods rely on a combination of pulmonary artery pressure and flow assessment; 
however, most studies describing these methods suffer from small sample study size, limited 
reliability across a broad range of patients, and do not take left atrial pressure into account. 
New methods such as ePLAR show promise, but require further study in large cohorts with 
differing forms of pulmonary hypertension.
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